Rare cancers account for ~25–30% of all cancer diagnoses and 25% of cancer deaths, representing a substantial burden of disease. However, basic science research, clinical trials and approval of new therapies for rare cancers are lacking. This translates into a worse prognosis for patients with a rare cancer than for those with common cancers. With the number of rare cancers increasing, finding more appropriate solutions for diagnosing, managing and studying rare cancers is essential.
Matthieu Foll presented the advances of the lungNENomics project with an oral talk entitled “Characterising ...
Matthieu Foll was invited to give a keynote lecture at 12th European Meeting on Molecular ...
Nicolas Alcala was invited to give the keynote lecture at Stanford’s Evolgenome seminar series for ...